Alberto Inga
Overview
Explore the profile of Alberto Inga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
2590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carvalho C, Silva R, Pinho E Melo T, Inga A, Saraiva L
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682165
This review delves into the significant cellular and molecular responses triggered by UVR exposure in human skin, emphasizing the pivotal role of mutant p53 (mutp53) in the carcinogenic process elicited...
2.
Borlak J, Ciribilli Y, Bisio A, Selvaraj S, Inga A, Oh J, et al.
J Transl Med
. 2024 Sep;
22(1):845.
PMID: 39285385
Background: Doxorubicin is an important anticancer drug, however, elicits dose-dependently cardiomyopathy. Given its mode of action, i.e. topoisomerase inhibition and DNA damage, we investigated genetic events associated with cardiomyopathy and...
3.
Kratochvilova L, Vojsovic M, Valkova N, Sislerova L, El Rashed Z, Inga A, et al.
Biosci Rep
. 2023 Dec;
43(12).
PMID: 38112096
Non-canonical secondary structures in DNA are increasingly being revealed as critical players in DNA metabolism, including modulating the accessibility and activity of promoters. These structures comprise the so-called G-quadruplexes (G4s)...
4.
Vojsovic M, Kratochvilova L, Valkova N, Sislerova L, El Rashed Z, Menichini P, et al.
Biochimie
. 2023 Oct;
216:14-23.
PMID: 37838351
The effect of mutations in the P53 family of transcription factors on their biological functions, including partial or complete loss of transcriptional activity, has been confirmed several times. At present,...
5.
LncRNA EPR regulates intestinal mucus production and protects against inflammation and tumorigenesis
Briata P, Mastracci L, Zapparoli E, Caputo L, Ferracci E, Silvestri A, et al.
Nucleic Acids Res
. 2023 Apr;
51(10):5193-5209.
PMID: 37070602
The long non-coding RNA EPR is expressed in epithelial tissues, binds to chromatin and controls distinct biological activities in mouse mammary gland cells. Because of its high expression in the...
6.
Zacchini F, Venturi G, De Sanctis V, Bertorelli R, Ceccarelli C, Santini D, et al.
Genome Biol
. 2022 Aug;
23(1):177.
PMID: 35996163
Background: Dyskerin is a nuclear protein involved in H/ACA box snoRNA-guided uridine modification of RNA. In humans, its defective function is associated with cancer development and induces specific post-transcriptional alterations...
7.
Rigoli M, Spagnolli G, Lorengo G, Monti P, Potestio R, Biasini E, et al.
Int J Mol Sci
. 2022 Jul;
23(14).
PMID: 35887312
The formation of a tetrameric assembly is essential for the ability of the tumor suppressor protein p53 to act as a transcription factor. Such a quaternary conformation is driven by...
8.
Chakraborty A, Cadix M, Relier S, Taricco N, Alaeitabar T, Devaux A, et al.
Genome Res
. 2022 Jul;
32(7):1271-1284.
PMID: 35858751
Intronic polyadenylation (IPA) isoforms, which contain alternative last exons, are widely regulated in various biological processes and by many factors. However, little is known about their cytoplasmic regulation and translational...
9.
Briata P, Caputo L, Zapparoli E, Marcaccini E, Passalacqua M, Brondolo L, et al.
Nucleic Acids Res
. 2022 Jun;
50(13):7608-7622.
PMID: 35748870
EPR is a long non-coding RNA (lncRNA) that controls cell proliferation in mammary gland cells by regulating gene transcription. Here, we report on Mettl7a1 as a direct target of EPR....
10.
Grinkevich V, Vema A, Fawkner K, Issaeva N, Andreotti V, Dickinson E, et al.
Front Mol Biosci
. 2022 Jun;
9:823195.
PMID: 35720128
Restoration of the p53 tumor suppressor for personalised cancer therapy is a promising treatment strategy. However, several high-affinity MDM2 inhibitors have shown substantial side effects in clinical trials. Thus, elucidation...